108 related articles for article (PubMed ID: 17825511)
21. Effective treatment of advanced multiple myeloma refractory to alkylating agents.
Barlogie B; Smith L; Alexanian R
N Engl J Med; 1984 May; 310(21):1353-6. PubMed ID: 6546971
[TBL] [Abstract][Full Text] [Related]
22. [IgA pemphigus accompanying multiple myeloma has disappeared following the treatment with bortezomib (Velcade), cyclophosphamide and dexamethasone. Case study and literature review].
Adam Z; Feit J; Krejcí M; Pour L; Vasků V; Cermáková Z; Mayer J; Hájek R
Vnitr Lek; 2009 Oct; 55(10):981-90. PubMed ID: 19947244
[TBL] [Abstract][Full Text] [Related]
23. Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents.
Chen CI; Masih-Khan E; Jiang H; Rabea A; Cserti-Gazdewich C; Jimenez-Zepeda VH; Chu CM; Kukreti V; Trudel S; Tiedemann R; Tsang R; Reece DE
Br J Haematol; 2013 Aug; 162(4):483-8. PubMed ID: 23772701
[TBL] [Abstract][Full Text] [Related]
24. Primary plasma cell leukemia occuring in the young.
Raj RS; Najeeb S; Aruna R; Pavithran K; Thomas M
Indian J Cancer; 2003; 40(3):116-7. PubMed ID: 14716116
[TBL] [Abstract][Full Text] [Related]
25. Amyloid deposition of systemic myeloma-associated amyloidosis excludes actinic elastotic material.
Wada N; Fujimoto N; Komatsu T; Tajima S; Ishibashi A
Eur J Dermatol; 2002; 12(6):607-8. PubMed ID: 12459542
[TBL] [Abstract][Full Text] [Related]
26. [Multiple myeloma with laryngeal affectation: an uncommon cause of dysphonia].
González Fernández A; Berasategui Fuertes M; Sanhueza Torres I; Larrea Ramírez A
An Sist Sanit Navar; 2023 Apr; 46(1):. PubMed ID: 37203316
[TBL] [Abstract][Full Text] [Related]
27. Malignant myelomatous pleural effusion with good response to combination chemotherapy.
Attili VS; Singh VP; Sundar S; Mehta H; Negi ML; Gogia A; Raju SH; Rai M
J Assoc Physicians India; 2007 Aug; 55():595-6. PubMed ID: 18019805
[TBL] [Abstract][Full Text] [Related]
28. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma.
Hussein MA; Baz R; Srkalovic G; Agrawal N; Suppiah R; Hsi E; Andresen S; Karam MA; Reed J; Faiman B; Kelly M; Walker E
Mayo Clin Proc; 2006 Jul; 81(7):889-95. PubMed ID: 16835968
[TBL] [Abstract][Full Text] [Related]
29. Characteristics of orbital multiple myeloma: a case report and literature review.
Burkat CN; Van Buren JJ; Lucarelli MJ
Surv Ophthalmol; 2009; 54(6):697-704. PubMed ID: 19709708
[TBL] [Abstract][Full Text] [Related]
30. [Significance of the circumferential involvement of the superior horn tip of the thyroid cartilage in pharyngo-laryngeal cancer].
Blandino A; Versace P; Salamone I; Pandolfo I
Radiol Med; 1997 Dec; 94(6):595-9. PubMed ID: 9524595
[TBL] [Abstract][Full Text] [Related]
31. [Pulmonary involvement in IgA multiple myeloma. A case report and review of the literature].
Conesa Bernal C; Pascual Lledó F; Calvo Bonachera J
Arch Bronconeumol; 1999 Jan; 35(1):54-5. PubMed ID: 10047924
[No Abstract] [Full Text] [Related]
32. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
Luo SK; Li J; Hong WD; Zhao Y; Tong XZ
Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805
[TBL] [Abstract][Full Text] [Related]
33. G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma.
van de Donk NW; de Weerdt O; Veth G; Eurelings M; van Stralen E; Frankel SR; Hagenbeek A; Bloem AC; Lokhorst HM
Leukemia; 2004 Jun; 18(6):1078-84. PubMed ID: 15085157
[TBL] [Abstract][Full Text] [Related]
34. Testicular invading refractory multiple myeloma during bortezomib treatment successfully treated with lenalidomide: a case report.
Miyao K; Sakemura R; Sakai T; Tsushita N; Kato T; Niimi K; Ono Y; Sawa M
Ann Hematol; 2014 Mar; 93(3):529-30. PubMed ID: 23820941
[No Abstract] [Full Text] [Related]
35. Cutaneous involvement in multiple myeloma and bortezomib.
Siniscalchi A; Fratoni S; Santeusanio G; Del Poeta G; de Fabritiis P; Caravita T
Ann Hematol; 2009 Nov; 88(11):1137-9. PubMed ID: 19259673
[No Abstract] [Full Text] [Related]
36. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.
Hussein MA; Wood L; Hsi E; Srkalovic G; Karam M; Elson P; Bukowski RM
Cancer; 2002 Nov; 95(10):2160-8. PubMed ID: 12412170
[TBL] [Abstract][Full Text] [Related]
37. Remission of collapsing focal segmental glomerulosclerosis following chemotherapy for myeloma.
Shah S; Cavenagh J; Sheaf M; Thuraisingham RC
Am J Kidney Dis; 2004 Feb; 43(2):e10-2. PubMed ID: 14750118
[TBL] [Abstract][Full Text] [Related]
38. Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients.
Buda G; Orciuolo E; Galimberti S; Pelosini M; Petrini M
Ann Hematol; 2011 Sep; 90(9):1115-6. PubMed ID: 21181162
[No Abstract] [Full Text] [Related]
39. [A case of meningeal myeloma associated with consciousness disorder].
Banba H; Shimizu T; Nakajima T; Mochizuki T
Nihon Naika Gakkai Zasshi; 1992 May; 81(5):726-7. PubMed ID: 1512503
[No Abstract] [Full Text] [Related]
40. Plasma cell leukemia 3 months after autologous blood cell transplantation for multiple myeloma.
Koskela K; Pelliniemi TT; Lakkala T; Remes K
Bone Marrow Transplant; 1998 Feb; 21(3):305-7. PubMed ID: 9489657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
